Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
10.3904/kjm.2025.100.2.61
- Author:
Hong Sang CHOI
1
;
Eun Hui BAE
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
- Publication Type:16
- From:Korean Journal of Medicine
2025;100(2):61-67
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Glucagon-like peptide 1 receptor agonists (GLP-1RA) significantly reduce the risk of cardiovascular disease. However, whether GLP-1RA improves clinically important renal outcomes is still unclear. In cardiovascular outcome trials of GLP-1RA, renal outcomes have been evaluated as secondary outcomes; however, their benefits have not been clarified, except for the effect of reducing albuminuria. Recently, the FLOW trial evaluated the renal benefits of GLP-1RA as a primary outcome in patients with diabetes and chronic kidney disease and showed a significant renoprotective effect. In this review, we discuss the renoprotective effects of GLP-1RA, summarize recently published research results, and describe the known mechanism of renal benefit and outlook.
